Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.
Han-Ah LeeHyun Woong LeeIn Hee KimSoo-Young ParkDong Hyun SinnJung Hwan YuYeon Seok SeoSoon Ho UmJoung Il LeeKwan Sik LeeChang-Hun LeeWon Young TakYoung Oh KweonWonseok KangYong-Han PaikJin-Woo LeeSang Jun SuhYoung-Kul JungBeom Kyung KimJun Yong ParkDo Young KimSang Hoon AhnKwang-Hyub HanHyung Joon YimSeung-Up KimPublished in: Alimentary pharmacology & therapeutics (2020)
The criterion of HBV-DNA level > 107 IU/mL may be useful to define immune-tolerant phase. In addition, an extremely low risk of HCC development was observed in patients with CHB in immune-tolerant phase.